A new brain signature for schizophrenia risk refines pharmacogenomics and drug targeting
A landmark neuroimaging study published in *Brain* has identified a distinct, neurodevelopmentally-grounded brain signature for individuals with cognitive basic symptoms (COGDIS), a key risk syndrome for schizophrenia. Using machine learning on structural MRI data from over 2,300 participants, researchers found that the COGDIS signature not only distinguished patients from healthy controls but also showed strong biological convergence with the brain pattern of established schizophrenia, unlike other risk definitions. This signature was predictable from a combination of polygenic risk, cognitive, and environmental factors, and its expression correlated with poorer functional outcomes, highlighting its prognostic value. The findings advocate for a biologically-informed stratification of psychosis risk, moving beyond heterogeneous clinical criteria to more precise, mechanism-based definitions.
Study Significance: This research directly informs the field of neuropharmacology and personalized medicine by providing a biologically-validated target for early intervention. For pharmacologists, the distinct COGDIS brain pattern and its associated polygenic risk profile, enriched for neurodevelopmental processes, offer a new framework for developing and testing novel therapeutics aimed at this specific vulnerability dimension. The ability to predict signature expression from biopsychosocial data underscores the potential for integrating neuroimaging biomarkers with pharmacogenomics to optimize clinical trials and tailor preventive drug therapies for high-risk individuals, ultimately improving therapeutic windows and reducing adverse drug reactions in this population.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
